With the UKs withdrawal from the European Union, NICE’s relationship with EMA and indeed, the para...
Read moreMaximising the cost-saving potential of biosimilars remains a topic of much interest to payers and p...
Read moreDiscussing the benefits of seeking early scientific advice and what companies need to take into cons...
Read moreWhat are the pro’s and cons of seeking NICE approval using the Medical Technologies Evaluation Pro...
Read morePharmaceutical companies are incorporating payer / HTA needs into their clinical and commercial laun...
Read moreHow to create, facilitate, and promote sustainable Health Technology Assessment (HTA) cooperation in...
Read moreThis study aims to understand the industry perspective on drivers and challenges for a successful la...
Read moreMedicine prices in Greece are set by the IRP. IRP is the process of using the prices in other countr...
Read moreIs the evidence base for high-cost CAR T-cell therapies Kymriah and Yescarta sufficient to be grante...
Read moreWe are delighted to say that we have received fabulous feedback, with responses from 15 industry exe...
Read more